RESEARCH USE ONLY: All products are for laboratory research purposes only. Not for human or animal consumption.
By using this site, you confirm you are 21+ and acknowledge these products are not FDA approved.
← Back to Research Library
Mechanism of Action
PT-141 (Bremelanotide, Vyleesi) selectively activates MC3R and MC4R in the hypothalamus, producing sexual arousal through central dopaminergic pathways rather than peripheral vascular mechanisms. FDA-approved (June 2019) for HSDD in premenopausal women.
Key Research Findings
- FDA-approved as Vyleesi: First CNS-acting treatment for hypoactive sexual desire disorder
- RECONNECT Phase III: Significant improvement in sexual desire and reduction in distress
- 52-week extension showed sustained efficacy with no new safety signals
Peer-Reviewed Studies (4)
Kingsberg SA, Clayton AH, et al.
Obstetrics and Gynecology (2019)
Bremelanotide significantly improved sexual desire and reduced distress (RECONNECT trials)
Simon JA, Kingsberg SA, et al.
Obstetrics and Gynecology (2019)
52-week extension showed sustained HSDD improvement with no new safety signals
Clayton AH, Althof SE, et al.
Women's Health (2016)
Established 1.75mg as optimal dose with significant increases in satisfying sexual events
Dhillon S, Keam SJ
Drugs (2019)
Regulatory review of development milestones leading to June 2019 FDA approval
Research Disclaimer: The studies referenced above are from publicly available peer-reviewed literature. Pepta Labs products are sold strictly for research purposes. They are not intended for human consumption, therapeutic use, or as dietary supplements. All information is provided for educational and research reference only.